Effects of radium-223 dichloride (Ra-223) on total alkaline phosphatase (ALP) and prostate-specific antigen (PSA) in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA trial

被引：0
|
作者：
Strauss, A. [1 ]
Heinrich, D. [2 ]
Parker, C. [3 ,4 ]
Shan, M. [5 ]
Wilhelm, S. [5 ]
Garcia-Vargas, J. [5 ]
O'Bryan-Tear, C. G. [6 ]
Sartor, O. [7 ]
机构：
[1] Univ Med Gottingen, Urol Klin, Gottingen, Germany
[2] Akershus Univ Hosp, Lorenskog, Norway
[3] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[4] Inst Canc Res, Sutton, Surrey, England
[5] Bayer Healthcare, Whippany, NJ USA
[6] Algeta ASA, Oslo, Norway
[7] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V553
引用
收藏
页码：177 / 178
页数：2
相关论文
共 50 条
  • [21] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial
    Paganelli, G.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Michalski, J. M.
    O'Sullivan, J. M.
    Parker, C.
    Garcia-Vargas, J. E.
    Sartor, A.
    Finkelstein, S. E.
    ANNALS OF ONCOLOGY, 2015, 26 : 62 - 62
  • [22] Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases
    Parker, C.
    Heinrich, D.
    Bottomley, D.
    Hoskin, P.
    Franzen, L.
    Solberg, A.
    Pawar, V.
    Reuning-Scherer, J.
    O'Bryan-Tear, C. G.
    Nilsson, S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S689 - S689
  • [23] 1.5-year posttreatment follow-up of radium-223 dichloride (Ra-223) safety in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases from the phase 3 ALSYMPCA study
    Kuczyk, M.
    Parker, C.
    Vogelzang, N.
    Sartor, O.
    Bottomley, D.
    Coleman, R.
    Skjorestad, I.
    Whaba, M.
    Nilsson, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 178 - 178
  • [24] 3-Year Follow-up of Chemotherapy Following Radium-223 Dichloride (Ra-223) in Castration-Resistant Prostate Cancer (CRPC) Patients (Pts) With Symptomatic Bone Metastases (Mets) From ALSYMPCA
    Koenig, E.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Voyelzang, N.
    Staudacher, K.
    Thuresson, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 86 - 86
  • [25] Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases
    Stroelin, P.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    Tear, C. G. O'Bryan
    Staudacher, K.
    Vargas, J. E. Garcia
    Zou, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [26] 3-year follow-up of chemotherapy following radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients (Pts) with symptomatic bone metastases (Mets) from ALSYMPCA
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N. J.
    Staudacher, K.
    Thuresson, M.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S477 - S477
  • [27] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [28] Updated Analysis of Radium-223 Dichloride (Ra-223) Impact on Survival, Safety, and Skeletal-Related Events in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases From the Phase 3 ALSYMPCA Trial
    Wedel, S.
    Kranert, T. W.
    Chodacki, A.
    Staudacher, K.
    Garcia-Vargas, J.
    Parker, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S190 - S190
  • [29] 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA
    Amadori, D.
    Rossetti, C.
    Aglietta, M.
    Messina, C.
    Versari, A.
    Vogelzang, N. J.
    Sartor, A.
    Coleman, R. E.
    Govi, S.
    Fang, F.
    Skjorestad, I.
    Nilsson, S.
    Parker, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 55 - 55
  • [30] External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial.
    Finkelstein, Steven E.
    Michalski, Jeff M.
    O'Sullivan, Joe M.
    Parker, Chris
    Garcia-Vargas, Jose E.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
12345